Search clinical trials for: ADT + Enzalutamide

Total 4784 results

Bayer

Recruiting

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide (ARAMON)

Biochemically Recurrent Prostate Cancer

United States
Alliance Foundation Trials, LLC.
Bayer

Recruiting

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)

Prostate Cancer | Metastatic Prostate Cancer | Prostate Cancer Metastatic | Castrate Resistant Prostate Cancer

United States
Astellas Pharma Inc

Active, not recruiting

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Progressive Metastatic Prostate Cancer

China, Hong Kong, Korea, Republic of, Taiwan
Corcept Therapeutics

Completed

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Metastatic Castration-Resistant Prostate Cancer

United States, United Kingdom
Benjamin Movsas, M.D.

Withdrawn

Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer (NSCLC)

Non-small Cell Lung Cancer Stage I

United States
Henry Ford Health System

Completed

Randomized Trial of Suicide Gene Therapy and Prostate Cancer (ReCAP)

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States
Rahul Aggarwal
Fortis Therapeutics, Inc.

Recruiting

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Bayer

Active, not recruiting

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Prostate Cancer

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (Polaris)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Prostate Cancer | Castration-Resistant Prostate Cancer

Russian Federation, Georgia
Boehringer Ingelheim

Completed

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Prostatic Neoplasms, Castration-Resistant

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Singapore, Hong Kong, Netherlands
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Belgium, France, Germany, Spain, United Kingdom
British Columbia Cancer Agency
Sanofi; Ozmosis Research Inc.

Unknown

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostatic Cancer

Canada, Australia
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Severe Hepatic Impairment | Normal Hepatic Function

Bulgaria
zr Pharma & GmbH

Completed

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP)

Metastatic Castration Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Lynch Syndrome

United States, Puerto Rico
Novartis Pharmaceuticals
Alliance Foundation Trials, LLC.; RTOG Foundation, Inc.

Active, not recruiting

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition)

Prostatic Neoplasms

United States, China, Canada, Spain, United Kingdom, Belgium, Japan, Taiwan, Germany, Singapore, Austria, Netherlands, Korea, Republic of, France, Switzerland, Denmark, Sweden, Poland, Czechia
University of Sydney
Canadian Cancer Trials Group; Australian and New Zealand Urogenital and Prostate... and other collaborators

Active, not recruiting

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET)

Prostatic Neoplasms

New Zealand, Canada, United States, Australia, United Kingdom, Ireland
Cedars-Sinai Medical Center

Completed

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Prostate Cancer

United States
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)

Castration-Resistant Prostate Cancer

United States, Canada, France, Spain, United Kingdom, Australia, Poland, Germany, Austria, Belgium, Netherlands, Italy, Chile, South Africa, Argentina
Astellas Pharma Global Development, Inc.
Medivation, Inc.

Approved for marketing

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Metastatic Castration-Resistant Prostate Cancer
Takeda

Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Alpha1-Antitrypsin Deficiency

Italy, United States, Poland, Portugal
University of Chicago
National Cancer Institute (NCI); Corcept Therapeutics

Recruiting

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Prostate Cancer

United States
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Castration Resistant Prostate Cancer | Prostate Carcinoma Metastatic to the Bone

United States
Astellas Pharma Global Development, Inc.
Medivation, Inc.

Terminated

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Metastatic Castration Resistant Prostate Cancer

United States
VZW Cardiovascular Research Center Aalst
AZ Sint-Jan AV

Unknown

Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation (POWDER-AF)

Atrial Fibrillation

Belgium
National Cancer Institute (NCI)

Terminated

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Prostate Neoplasms | Metastatic Castration Resistant Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Ann Arbor Stage I Mantle Cell Lymphoma | Ann Arbor Stage II Mantle Cell Lymphoma | Ann Arbor Stage III Mantle Cell Lymphoma | Ann Arbor Stage IV Mantle Cell Lymphoma

United States
Bayer

Completed

An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States (ARENA)

Non-metastatic Prostate Cancer | Non-metastatic Castration-resistant Prostate Cancer

United States
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (STEP-D222)

Major Depressive Disorder

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer | Early Stage

United States
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate | Prostatic Neoplasm | Progressive mCRPC

United States, Canada
Bayer

Completed

Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.

Cerebrovascular Circulation

United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage I Renal Cell Cancer

United States
Eli Lilly and Company
Sarah Cannon Development Innovations

Completed

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Prostate Cancer Metastatic

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Alpha1-Antitrypsin Deficiency

United States, Belgium, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Spain, Portugal, Italy, Poland, Brazil
AbbVie

Completed

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Japan
University of Washington

Recruiting

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Refractory Mantle Cell Lymphoma | Recurrent Follicular... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Metastatic Hormone-Sensitive Prostate Cancer

China
Swiss Group for Clinical Cancer Research

Terminated

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Prostate Cancer | Cancer of the Prostate

Switzerland
OHSU Knight Cancer Institute
United States Department of Defense; Oregon Health and Science University

Completed

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone

United States
Asan Medical Center

Unknown

The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer

Castration-resistant Prostate Cancer

Korea, Republic of
The Swedish School of Sport and Health Sciences
Karolinska Institutet; Sahlgrenska University Hospital, Sweden; Prostate Cancer... and other collaborators

Recruiting

Training for Men Undergoing Androgen Deprivation Therapy. (ADT-train)

Prostate Cancer

Sweden
Changhai Hospital

Recruiting

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer

Treatment

China
San Diego State University
National Institute of Mental Health (NIMH)

Completed

Attention Disengagement Training for Social Phobia (SPAttn)

Social Anxiety Disorder

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Neoadjuvant Therapy | High Risk Prostate Cancer | Locally Advanced Prostate Cancer | Intense Endocrine Therapy

China
Emergent BioSolutions
Walter Reed Army Institute of Research (WRAIR)

Terminated

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

Adenoviral Infection

United States

Search clinical trials for: ADT + Enzalutamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations